CompletedPhase 2ACTRN12610000780055

Pioglitazone in the treatment of acromegaly

The effects on insulin-like growth factor 1 (IGF-1) and growth hormone levels using Pioglitazone in the treatment of active acromegaly

Sponsor

Auckland district health board

Enrollment

20 participants

Start Date

Jun 1, 2009

Study Type

Interventional

Conditions

To study the effects of pioglitazone (3 months at maximum dose of 45mg) on disease activity of acromegaly, as measured by IGF-1 level.

Sex: Both males and females

Active acromegaly - clinical features, elevated IGF-1 and/or non-suppressible growth hormone (>1mcg/L) after 75g oral glucose.

Initiation or discontinuation of octreotide in the last 6 months
Initiation or discontinuation of cabergoline in the last 3 months if treatment caused >20% change in serum IGF-1
Congestive heart failure (New York Heart Association (NYHA)Grade 2 or above)
Current thiozolidinedione use
Current malignancy
Clinical liver disease

Interested in this trial?

Get notified about updates and connect with the research team.

Pioglitazone - 1month run in period of 15mg (2 weeks) and 30mg (2 weeks)orally daily, then target dose of 45mg orally daily for further 3 months

New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

ACTRN12610000780055